Published in J Urol on March 14, 2009
Effect of ADT in Chinese Male With Prostate Cancer | NCT04341324
Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol (2013) 3.85
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol (2010) 1.99
Treatment and prevention of bone complications from prostate cancer. Bone (2010) 1.60
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis (2013) 1.23
Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol (2010) 1.13
High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res (2010) 1.11
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes (2010) 1.09
Diabetes and risk of cancer. ISRN Oncol (2013) 1.06
Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol (2011) 1.03
Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol (2012) 1.03
High-density lipoprotein and prostate cancer: an overview. J Epidemiol (2013) 0.97
LHRH Agonists for the Treatment of Prostate Cancer: 2012. Rev Urol (2012) 0.96
Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl (2012) 0.95
Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl (2012) 0.92
Malignancy-associated dyslipidemia. Open Cardiovasc Med J (2011) 0.86
Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer (2010) 0.85
Prostate cancer: The androgen receptor remains front and centre. Nat Rev Clin Oncol (2013) 0.85
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol (2013) 0.85
Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer. Front Oncol (2015) 0.84
National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy. Can Urol Assoc J (2014) 0.83
Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management. ISRN Urol (2013) 0.82
Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J (2011) 0.82
Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man. Int J Clin Pract Suppl (2010) 0.81
Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes (2014) 0.81
Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol (2014) 0.80
Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One (2015) 0.80
Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy? Rep Pract Oncol Radiother (2014) 0.80
Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. Sci Rep (2016) 0.78
Metabolic risk factors in prostate cancer. Cancer (2010) 0.78
A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma. Acta Pharmacol Sin (2011) 0.77
The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study. J Cancer Res Clin Oncol (2013) 0.77
Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. Front Endocrinol (Lausanne) (2013) 0.76
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones. Asian J Androl (2015) 0.75
Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: A prospective, longitudinal study. Can Urol Assoc J (2017) 0.75
Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Sci Rep (2016) 0.75
A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. BMC Cancer (2015) 0.75
The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol (2016) 0.75
Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate Int (2016) 0.75
Hormone naïve prostate cancer: predicting and maximizing response intervals. Asian J Androl (2015) 0.75
Cancer: ADT and acute kidney injury-causal or casual relationship? Nat Rev Endocrinol (2013) 0.75
Contemporary Role of the Decipher® Test in Prostate Cancer Management: Current Practice and Future Perspectives. Rev Urol (2016) 0.75
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. Rheumatol Int (2014) 0.75
Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy. World J Urol (2012) 0.75
Nationwide population-based cohort study on the association of acute coronary syndrome in patients with malignancies. Support Care Cancer (2014) 0.75
Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. Int J Clin Oncol (2015) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care (1999) 26.39
Standards of medical care in diabetes--2008. Diabetes Care (2008) 17.23
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2005) 11.91
Obesity and diabetes in the developing world--a growing challenge. N Engl J Med (2007) 10.54
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Diagnosis and classification of diabetes mellitus. Diabetes Care (2006) 7.91
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys (2005) 5.44
Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med (1996) 5.20
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol (2006) 4.36
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol (2008) 4.11
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer (2007) 3.92
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest (1997) 3.66
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer (2005) 3.56
Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med (2005) 3.29
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol (2006) 3.09
Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2003) 3.07
Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab (2006) 2.98
The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol (2005) 2.92
Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab (1999) 2.79
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis (2008) 2.56
Noncancer deaths in white adult cancer patients. J Natl Cancer Inst (1993) 2.28
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008) 2.16
Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med (2004) 2.12
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) (2003) 2.07
Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology (2004) 2.01
Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation (1998) 1.98
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer (2005) 1.72
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol (2008) 1.72
Update on obesity. J Clin Endocrinol Metab (2008) 1.65
The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int (2006) 1.58
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology (2008) 1.53
Testosterone, body composition and aging. J Endocrinol Invest (1999) 1.42
Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab (2007) 1.27
Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism (1990) 1.13
Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab (2000) 1.03
Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: how real is the risk? J Clin Oncol (2007) 0.81
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol (2014) 3.17
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol (2008) 2.68
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol (2008) 2.20
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Management of complications of prostate cancer treatment. CA Cancer J Clin (2008) 1.91
Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer (2005) 1.72
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol (2010) 1.66
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol (2012) 1.65
Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol (2012) 1.64
Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer (2004) 1.64
Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res (2004) 1.63
Treatment and prevention of bone complications from prostate cancer. Bone (2010) 1.60
Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int (2008) 1.59
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2014) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Clinical decisions. Screening for prostate cancer. N Engl J Med (2012) 1.49
Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int (2010) 1.40
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res (2013) 1.33
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32
Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol (2011) 1.31
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer (2007) 1.28
Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol (2011) 1.27
Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology (2002) 1.22
Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol (2013) 1.21
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist (2007) 1.16
Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol (2005) 1.10
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes (2010) 1.09
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J (2013) 1.09
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer (2009) 1.09
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol (2008) 1.08
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2012) 1.07
A structured exercise program for patients with advanced non-small cell lung cancer. J Thorac Oncol (2009) 1.06
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int (2010) 1.04
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med (2009) 1.03
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma (2007) 1.02
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00
Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer (2012) 0.99
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs (2006) 0.95
Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist (2012) 0.92
Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology (2008) 0.92
Selective estrogen receptor modulators to prevent treatment-related osteoporosis. Rev Urol (2005) 0.90
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer (2011) 0.90
Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw (2010) 0.90
Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem (2008) 0.88
Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol (2010) 0.88
Novel bone-targeted strategies in oncology. Clin Cancer Res (2010) 0.88
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin (2010) 0.88
Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res (2012) 0.87
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol (2012) 0.87
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology (2002) 0.86
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res (2005) 0.86
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer (2006) 0.85
Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer (2010) 0.85
Effective treatment for early-stage prostate cancer--possible, necessary, or both? N Engl J Med (2011) 0.83
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol (2004) 0.82
Ultraviolet index and racial differences in prostate cancer incidence and mortality. Cancer (2013) 0.82
Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am (2012) 0.80
Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol (2010) 0.80
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res (2006) 0.80
Antitumor activity of bisphosphonates. Clin Cancer Res (2003) 0.80
Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol (2012) 0.79
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet (2014) 0.79
Changes in PSA kinetics after DNA vaccine therapy-not so fast! J Clin Oncol (2009) 0.78
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology (2003) 0.78
Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol (2004) 0.78
The role of bisphosphonates in the management of metastatic prostate cancer. Curr Oncol Rep (2003) 0.78
Intercurrent infection predicts mortality in patients with late hepatic artery thrombosis listed for liver retransplantation. Liver Transpl (2012) 0.78
Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs (2011) 0.77
Prostate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol (2009) 0.77
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist (2012) 0.77
Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? Clin Cancer Res (2013) 0.76
Genitourinary malignancies. Cancer Chemother Biol Response Modif (2003) 0.76
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis. J Osteoporos (2011) 0.76
Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past? J Clin Oncol (2008) 0.75
Osteoporosis in men with prostate cancer: now for the fracture data. J Clin Oncol (2008) 0.75